Free shipping on all orders over $ 500

AZD6765

Cat. No. M1897
AZD6765 Structure
Size Price Availability
10mg USD 180  USD180 Out of stock
50mg USD 480  USD480 Out of stock
200mg USD 900  USD900 Out of stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

AZD6765, a low-trapping NMDA channel blocker in development for major depression, is predicted to have an improved tolerability profile compared to ketamine. Preclinically, NMDA channel blockers increase gamma-band EEG - a potential therapeutic biomarker of cortical disinhibition. Significant increases in gamma-band EEG were observed at 1 hour for AZD6765 and ketamine, and baseline-corrected gamma-band EEG following AZD6765 150 mg was statistically indistinguishable from that observed following ketamine. AZD6765 demonstrated NMDA channel blockade and an improved tolerability profile compared to ketamine. AZD6765 demonstrated NMDA channel blockade and an improved tolerability profile compared to ketamine.

Chemical Information
Molecular Weight 198.26
Formula C13H14N2
CAS Number 153322-05-5
Form Liquid
Solubility (25°C) DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Ioline D Henter, et al. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status

[2] Vivian B Neis, et al. The involvement of PI3K/Akt/mTOR/GSK3β signaling pathways in the antidepressant-like effect of AZD6765

[3] Samuel T Wilkinson, et al. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems

[4] Ioline D Henter, et al. Glutamatergic Modulators in Depression

[5] Lorenz Deutschenbaur, et al. Role of calcium, glutamate and NMDA in major depression and therapeutic application

Related GluR Products
LY367385 hydrochloride

LY367385 hydrochloride is a highly selective and potent mGluR1a antagonist, with an IC50 of 8.8 μM for inhibiting of quisqualate-induced phosphoinositide (PI) hydrolysis, compared with >100 μM for mGlu5a.

PDZ1 Domain inhibitor peptide

PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95).

CALP1

CALP1 is a calmodulin (CaM) agonist (Kd of 88 µM) with binding to the CaM EF-hand/Ca2+-binding site.

NT 13

NT 13 (TPPT) is a tetrapeptide having the amino acid sequence L-threonyl-L-prolyl-L-prolyl-L-threonine amide.

Tat-NR2Baa

Tat-NR2BAA is the control peptide of Tat-NR2B9c, inactive.

  Catalog
Abmole Inhibitor Catalog




Keywords: AZD6765 supplier, GluR, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.